An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Stopped The study was discontinued due to slow recruitment and subjects not completing follow up period.

Conditions

• Colorectal Neoplasms

Interventions

• DRUG: Cetuximab

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

• [object Object]